L

Lirio

Behavioral-AI health engagement personalisation engine

Vice President - Life Science Sales

Full-Time
$180k - $200k/yr+ Incentives
Expert
Remote in USA
RemoteRequires 25–50% travel.
Sales & Account ManagementAccount Executive

About the job

Requirements
  • At least 10 years of relevant sales experience, preferably in earlier-stage virtual or digital health companies or as a clinician working with Life Science organizations.
  • A proven ability to cultivate collaborative relationships across key account functions, including Product, Clinical, National Accounts, Network, and Legal.
  • Experience selling artificial intelligence or machine learning solutions at an early-stage healthcare technology company.
  • Experience working with small and medium-sized businesses, biotech companies, and large pharmaceutical companies.
  • Experience with complex contract negotiations within Life Science procurement processes.
  • Ability to work independently.
  • Project management, organizational, communication, meeting preparation, and follow-up skills.
  • Public speaking skills and willingness to present to large audiences when needed.
  • Ability to manage multiple priorities in a fast-paced environment.
  • A firm understanding of healthcare economics and trends, specifically across enterprise health systems and health plans.
  • Fluency in relationship-building, particularly with key decision-makers.
  • Ability to switch between virtual and in-person sales calls when necessary.
Responsibilities
  • Drive new sales with target Life Science accounts by developing strategies that increase top-of-funnel activity and efficiently move prospects through each stage of the sales funnel to close.
  • Understand the network synergy among Life Science organizations, health systems, payers, consultants, and other influencers, and use that influence to advance deals.
  • Work cross-functionally within the company to identify and solve gaps that will help move deals forward faster.
  • Generate interest in Lirio by building relationships with C-level executives in target accounts.
  • Update and maintain the sales pipeline in the company customer relationship management system, Salesforce.
  • Build trusted-advisor relationships with prospective clients by focusing on key issues and strategic initiatives and keeping Lirio relevant to executive teams.
Desired Qualifications
  • Prior experience with ZoomInfo, HubSpot, and Salesforce.

About the company

Lirio uses behavioral science and AI to improve patient engagement and health outcomes. Its Precision Nudging personalisation engine analyzes individual behaviors, communication patterns, and social/clinical context to deliver hyper-personalized messages and interventions that encourage adherence and screenings. By moving beyond demographics, it enables real-time, one-to-one outreach to sustain engagement across care journeys, partnering with health systems, payers, and provider organizations. The goal is to reduce gaps in care and lower total cost of care by guiding patients through their evolving healthcare journey.

Company Size

51-200

Company Stage

N/A

Total Funding

$33.1M

Headquarters

Knoxville, Tennessee

Founded

2017

Get referred to Lirio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Lirio launched Precision Nudging for Life Sciences on February 5, 2026.
  • Truth Initiative's EX partnership and Bon Secours case study validate real enterprise demand.
  • Headcount reached 127 in March 2026, and job postings increased 37%.

What critics are saying

  • Health systems still struggle customizing outreach; Lirio sells into that stalled market.
  • Lirio lacks disclosed 2026 funding; scaling sales and R&D stays capital constrained.
  • Microsoft or larger CRM vendors can commoditize hyper-personalized nudging, erasing Lirio's standalone platform.

What makes Lirio unique

  • Lirio combines behavioral science with agentic AI across healthcare and life sciences.
  • Microsoft Marketplace listings in 2025-2026 make Precision Nudging easier to deploy.
  • PAIHA membership links Lirio with payers, providers, pharma, and health systems.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Company Match
  • 10 paid holidays + holiday week company closure
  • Unlimited Paid Time Off
  • Hybrid Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

1%

2 year growth

0%
Business Wire
Feb 5th, 2026
Life sciences firms struggle with patient engagement as 70% cite adherence challenges costing $100B annually

Lirio, a behavioural science and AI platform, has released research revealing that traditional personalisation approaches in life sciences fail to improve patient engagement. The survey of over 75 life sciences executives, conducted by Sage Growth Partners, found that more than 70% identified clinical trial engagement and medication adherence as persistent challenges. The report highlights that nearly 50% of patients don't take medications as prescribed, contributing to $100 billion in annual preventable healthcare costs and 125,000 avoidable deaths. Despite growing direct-to-consumer strategies, only half of organisations use digital health technologies for patient engagement, and fewer than 3% partner with specialised vendors. The findings come as new regulations reshape pharmaceutical advertising, prompting life sciences companies to rethink patient engagement strategies beyond traditional mass messaging approaches.

Teknovation.biz
May 5th, 2025
Lirio Releases Report Titled (Re)Defining Personalization

Lirio, the Knoxville-based pioneer in the union of behavioral science and artificial intelligence to deliver better health outcomes, has released new industry findings on the significant impact that advanced health... The post Lirio releases report titled (Re)defining Personalization appeared first on Teknovation.biz.

U.S. Securities and Exchange Commission
May 2nd, 2025
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

U.S. Securities and Exchange Commission
May 2nd, 2025
SEC FORM D/A

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Silverwood Partners
Feb 8th, 2024
Healthcare Private Placement and M&A Transactions Review Week Ending Feb 4, 2024 | Silverwood Partners

Strategy | Financing Transactions Private Placement / Financing Transactions Cellanome: The company raised $150 million of Series B venture funding from Premji Invest (US) and undisclosed investors on January 29, 2024, putting the company’s pre-money valuation at $375 million. The company is a developer of a unique multi-omics platform designed to measure biology at an unprecedented […]